Difference between revisions of "Actinium Ac 225 lintuzumab (Actimab-A)"
Jump to navigation
Jump to search
m |
m |
||
(2 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
===[[Acute myeloid leukemia]]=== | ===[[Acute myeloid leukemia]]=== | ||
− | ==Also | + | ==Also known as== |
*'''Brand name:''' Actimab-A | *'''Brand name:''' Actimab-A | ||
Line 11: | Line 11: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | |||
[[Category:Radiotherapy medications]] | [[Category:Radiotherapy medications]] | ||
− | [[Category:Anti-CD33 | + | [[Category:Anti-CD33 radioimmunoconjugates]] |
− | [[Category:Acute myeloid leukemia medications]] | + | [[Category:Acute myeloid leukemia medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] |
Latest revision as of 21:05, 30 June 2023
Mechanism of action
Monoclonal antibody directed against CD33 with a radioactive agent attached.
Preliminary data
Acute myeloid leukemia
Also known as
- Brand name: Actimab-A